WARSAW, Ind., Sept. 9, 2019 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global leader in
musculoskeletal healthcare, today announced FDA 510(k) clearance
for the Persona® Revision Knee System for revision knee
replacement procedures. The Company expects to launch the system
for patients in the United States
over the coming weeks. This revision system offers anatomic
components designed to match a patient's anatomy for a personalized
fit. Available with a modern, intuitive instrumentation platform,
the Persona Revision Knee System enables surgeons to take a
personalized approach to addressing simple to complex revision
procedures by offering the flexibility to utilize their preferred
surgical approach.
The Persona Revision Knee System utilizes Zimmer Biomet's
proprietary technologies that are designed to enhance optimal fit
and function:
- Zimmer Biomet's Trabecular Metal™ Technology, a
unique, highly porous biomaterial made from elemental tantalum with
structural, functional and physiological properties similar to that
of bone, is the only tantalum-based porous material on the market
with over 20 years of history making it one of the most clinically
documented technologies.1-3
- Vivacit-E® Highly Crosslinked Polyethylene (HXPE), a
bearing surface with actively stabilized Vitamin E designed to
protect against oxidation and maintain wear resistance and strength
throughout the life of the implant.
"Persona Revision completes Zimmer Biomet's flagship Persona
knee system and enhances our ecosystem of customer-centric
solutions that address the needs of our customers and improve
patient outcomes," said Ivan Tornos, Zimmer Biomet's Group
President of Global Orthopedics. "The highly-anticipated release of
Persona Revision provides surgeons with a full portfolio for the
continuum of knee arthroplasty care and the ability to truly tailor
an implant solution based on each patient's unique
requirements."
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global
leader in musculoskeletal healthcare. We design, manufacture and
market orthopedic reconstructive products; sports medicine,
biologics, extremities and trauma products; office-based
technologies; spine, craniomaxillofacial and thoracic products;
dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at
www.twitter.com/zimmerbiomet.
References:
- Bobyn, et al., Characterization of a New Porous
Tantalum Biomaterial for Reconstructive Orthopaedics. 66th Annual
AAOS 1999.
- Zhang, et al., Interfacial Frictional Behavior:
Cancellous Bone, Cortical Bone, and a Novel Porous Tantalum
Biomaterial. Journal of Musculoskeletal Research. 3:4,
245-251, 1999.
- Karageorgiou and Kaplan. Porosity of Biomaterial Scaffolds and
Osteogenesis. Biomaterials. 26: 5474-91, 2005.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements concerning
Zimmer Biomet's expectations, plans, prospects, and product and
service offerings, including new product launches and potential
clinical successes. Such statements are based upon the current
beliefs and expectations of management and are subject to
significant risks, uncertainties and changes in circumstances that
could cause actual outcomes and results to differ materially. For a
list and description of some of such risks and uncertainties, see
Zimmer Biomet's periodic reports filed with the Securities and
Exchange Commission (SEC). These factors should not be construed as
exhaustive and should be read in conjunction with the other
cautionary statements that are included in Zimmer Biomet's filings
with the SEC. Forward-looking statements speak only as of
the date they are made, and Zimmer Biomet disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Readers of this news release are cautioned not to rely on these
forward-looking statements, since there can be no assurance that
these forward-looking statements will prove to be accurate. This
cautionary statement is applicable to all forward-looking
statements contained in this news release.
ZBH-Corp
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zimmer-biomet-commences-commercial-release-of-persona-revision-knee-system-300913747.html
SOURCE Zimmer Biomet Holdings, Inc.